CAMBRIDGE, Mass.–(BUSINESS WIRE)–Blackstone Life Sciences (“BXLS”) today announced a $455 million collaboration with Boston Scientific Corporation (NYSE: BSX) to co-fund the development of the VITALYST™ Temporary Percutaneous Transvalvular Circulatory Support System program. The VITALYST system is a next-generation, miniature heart pump intended to increase cardiac output and improve blood flow from the heart to the brain and other vital organs. It is designed to treat acute myocardial infarc
Tag: Boston Scientific
SIMPLAAFY study of the WATCHMAN FLX™ Pro Left Atrial Appendage Closure Device meets primary endpoints
Both post-implant monotherapies in the trial achieved non-inferiority compared to dual anti-platelet therapy (DAPT) supporting the potential to simplify post-procedure drug regimens MARLBOROUGH, Mass. and SAN DIEGO, Nov. 2, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX)…
Boston Scientific announces strategic investment in MiRus LLC
Agreement includes exclusive option to acquire novel, balloon-expandable transcatheter aortic valve made with proprietary rhenium alloy MARLBOROUGH, Mass., May 18, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has invested $1.5 billion in return for an…
Boston Scientific announces agreement to acquire Penumbra, Inc.
Acquisition to expand Boston Scientific’s cardiovascular portfolio and further address increasing prevalence of vascular diseases Provides scaled entry into mechanical thrombectomy and neurovascular, key strategic adjacencies Conference call at 8:00 a.m. ET to discuss details of the transaction MARLBOROUGH, Mass. and ALAMEDA, Calif., Jan. 15, 2026 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) and Penumbra, Inc., […]
The FARAPULSE™ Pulsed Field Ablation System Demonstrates Superior Efficacy in Patients Treated for Paroxysmal Atrial Fibrillation
New findings from the SINGLE SHOT CHAMPION trial (NCT05534581), presented at EHRA 2025 and published in the New England Journal of Medicine, showed the FARAPULSE™ Pulsed Field Ablation (PFA) System to be superior in reducing atrial arrhythmia (AA) recurrence for treating symptomatic, drug-refractory paroxysmal atrial fibrillation (PAF) compared to the Artic Front Advance™ cardiac cryoablation catheter. […]
Ajax Health and KKR Form New Platform to Develop System for Treating Heart Failure
MENLO PARK, Calif., March 4, 2025 /PRNewswire/ — Ajax Health, a KKR-backed medical device platform, today announced the formation of a new entity, FlowMod. The new organization is the result of a collaboration between Boston Scientific Corporation, Ajax Health, and KKR, utilizing…
Boston Scientific announces agreement to acquire SoniVie Ltd.
Acquisition to expand Interventional Cardiology Therapies offerings with ultrasound-based renal denervation therapy for treatment of hypertension MARLBOROUGH, Mass., March 3, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced it has entered into a definitive…
Late-breaking data presented at AF Symposium 2025 highlight key Boston Scientific therapies for management of patients with atrial fibrillation
First phase of ADVANTAGE AF clinical trial achieves safety and effectiveness endpoints for treatment of drug-resistant, symptomatic, persistent atrial fibrillation with the FARAPULSE™ Pulsed Field Ablation System Sub-analysis from OPTION clinical trial highlights consistent safety and…
Boston Scientific Announces Agreement to Acquire Bolt Medical, Inc.
Acquisition to expand cardiovascular portfolio with complementary and differentiated calcium modification platform, furthering company’s strategy to address coronary and peripheral disease MARLBOROUGH, Mass., Jan. 8, 2025 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today…
Boston Scientific WATCHMAN FLX™ Left Atrial Appendage Closure Device Demonstrates Superior Bleeding Risk Reduction to Oral Anticoagulation Following a Cardiac Ablation in the OPTION Clinical Trial
Data also demonstrates that the stroke risk reduction device is as effective as oral anticoagulants for patients with atrial fibrillation following a cardiac ablation MARLBOROUGH, Mass. and CHICAGO, Nov. 16, 2024 /PRNewswire/ — Boston Scientific Corporation (NYSE: BSX) today announced…



